Judicious Use of Benzodiazepines
The judicious prescribing of benzodiazepines is crucial in addressing the significant public health concern surrounding their use. In the United States, approximately 30.6 million adults report using benzodiazepines. Of these, around 5.3 million engage in benzodiazepine abuse, which can lead to addiction and serious health risk. This document highlights the key issues, dispels common myths, and outlines effective prescribing principles to reduce risks associated with benzodiazepine use. By focusing on risk reduction strategies and incorporating appropriate first-line treatments for conditions such as anxiety and insomnia, healthcare providers can ensure safe and effective patient outcomes. Educating patients and adopting a cautious approach is paramount in preventing misuse and ensuring responsible prescribing practices.
- Myth: Benzodiazepines are effective as the first-line treatment for anxiety and insomnia.
Fact: They should only be used for severe anxiety and insomnia over the short term. For anxiety, effectiveness diminishes after 4-6 weeks; for insomnia, recommended duration is 1-2 weeks. - Myth: Low doses of benzodiazepines are not addictive.
Fact: Physical dependence can occur at any dose, often leading to use aimed at preventing withdrawal symptoms rather than treating the original condition. - Myth: Ambien is a safer alternative to benzodiazepines.
Fact: Like benzodiazepines, Ambien binds to GABA receptors and is not recommended for long-term use due to a lack of evidence for its efficacy and safety, particularly in older adults who are at increased risk of falls.
- Restricted Duration and Indication: Prescribe benzodiazepines only when clinically necessary, specifically for severe anxiety or insomnia, and limit use to short durations—2-4 weeks for anxiety and 1-2 weeks for insomnia—to minimize effectiveness decline and dependency risks.
- Comprehensive Patient Assessment: Conduct thorough evaluations of patients' medical histories, existing medications, and substance use backgrounds to prevent drug interactions and assess potential for over-sedation.
- Conservative and Educational Prescribing: Maintain a conservative prescribing philosophy, coupled with patient education on risks, alternative treatments, and the importance of avoiding opioid co-prescriptions to prevent compounded risks.
- Interdisciplinary Collaboration and Ongoing Assessments: Engage an interdisciplinary care team for continuous assessment and support, integrating psychosocial considerations to aid in patient adherence and monitor treatment outcomes effectively.
- Detailed Substance Use History Evaluation: Conduct thorough reviews of past and present substance use histories, which is crucial for identifying potential risk factors and tailoring benzodiazepine treatment plans accordingly to prevent misuse and enhance patient safety.
- Appropriate First-line Treatments: Prioritize non-benzodiazepine medications such as SSRIs and SNRIs for anxiety and insomnia to address the primary condition effectively and reduce reliance on benzodiazepines.
- Taper Off Long-term Benzodiazepine Usage: Implement a structured plan to gradually reduce benzodiazepine dosage in patients who have been on the medication long-term. This approach helps mitigate withdrawal symptoms and minimizes dependency risks.
- Patient Education and Alternative Options: Educate patients on potential risks associated with benzodiazepine use and emphasize the importance of adhering to prescribed guidelines. Discuss alternative treatment options and strategies to support transition away from long-term benzodiazepine use.
- Patient Education and Counseling: Adopt an educational role by informing patients about the potential risks associated with benzodiazepine use, emphasizing the importance of adhering to short-term treatment protocols, and discussing alternative therapeutic options to enhance understanding and compliance.
- Professional Collaboration and Consultation: Engage in regular consultations with colleagues, including interdisciplinary team members such as medical, pharmacy, and behavioral specialists, to evaluate and refine benzodiazepine prescribing practices, ensuring a comprehensive approach to patient care and risk mitigation.
- Conservative Prescribing Practices: Maintain a conservative approach to benzodiazepine prescribing by integrating educational discussions during patient interactions, focusing on effective communication to address concerns, and setting clear expectations for treatment goals and limitations within the care coordination framework.
- Ongoing Assessment and Medication Adjustment: Implement continuous evaluations of patient responses to benzodiazepine treatment, allowing for timely adjustments in dosage or medication type to ensure optimal therapy outcomes while minimizing risks of dependency and adverse effects.
- Regular Consultation with an Interdisciplinary Team: Engage with a team of medical, pharmacy, and behavioral health professionals to collaboratively monitor patient progress and make informed decisions based on comprehensive clinical insights and shared expertise.
- Patient Engagement and Education: Maintain open communication with patients, offering educational resources and support to empower them in managing their treatment effectively and understanding the importance of compliance with prescribed guidelines.
Questions? We're here to help.
Whether you have a question or are interested in learning more about how we can best support you, please call our National Provider Services Line at 800-397-1630, Monday to Friday, 8 a.m. to 8 p.m. Eastern time.
Join the Carelon Behavioral Health provider network
Please submit an application today to get started.
